The incidence and quantity of antiidiotypic antibody formation after OKT3 monoclonal therapy in heart-transplant recipients.
Hesse
C J
CJ
Department of Internal Medicine I, Erasmus University, Rotterdam, The Netherlands.
Heyse
P
P
Stolk
B J
BJ
Balk
A H
AH
Jutte
N H
NH
Mochtar
B
B
Weimar
W
W
D000888:Antibodies, Anti-Idiotypic / Q000032:analysis*; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003524:Cyclosporins / Q000627:therapeutic use; D004797:Enzyme-Linked Immunosorbent Assay; D005455:Fluorescent Antibody Technique; D016027:Heart Transplantation / Q000276:immunology*; D006801:Humans; D007165:Immunosuppression Therapy; D016853:Muromonab-CD3; D011241:Prednisone / Q000627:therapeutic use; D014184:Transplantation, Homologous
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D003524:Cyclosporins; D016853:Muromonab-CD3; D001379:Azathioprine; D011241:Prednisone